ArticleInfection and drug resistance2025

Metabolic Health Consequences of Switching to the Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir Plus Lamivudine Regimens in Virologically Suppressed People Living with HIV Aged > 40 Years: A Retrospective Real-World Study.

Jinchuan Shi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.